24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
FLULIEVA 50MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | FLULIEVA 50MG |
|---|---|
| Composition | Fludarabine Phosphate for Injection 50mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
FLULIEVA 50MG (Fludarabine Phosphate for Injection 50mg) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
FLULIEVA 50 MG (Fludarabine Phosphate for Injection 50 mg) is a prescription anticancer medicine used for the treatment of certain blood cancers and hematological disorders, particularly Chronic Lymphocytic Leukemia (CLL) and selected lymphoproliferative conditions. It contains Fludarabine Phosphate 50 mg, a chemotherapy medicine that belongs to the class of drugs known as purine analog antimetabolites. The medicine works by interfering with the growth and multiplication of abnormal cancer cells, helping to slow disease progression and improve treatment outcomes.
Blood cancers occur when abnormal white blood cells grow uncontrollably and accumulate in the blood, bone marrow, lymph nodes, or other organs. These abnormal cells interfere with the body's ability to produce healthy blood cells and fight infections effectively. FLULIEVA 50 MG targets these cancerous cells by disrupting DNA synthesis, preventing them from multiplying and surviving.
Fludarabine has become an important medicine in modern hematology and oncology because of its effectiveness in treating specific leukemias and lymphoid malignancies. It is often used alone or in combination with other anticancer medicines as part of specialized treatment protocols.
FLULIEVA 50 MG is commonly prescribed for:
The medicine may be recommended when patients require systemic therapy to control disease progression or when previous treatments have not provided adequate results.
Manufactured under strict pharmaceutical quality standards, FLULIEVA 50 MG is designed to provide reliable therapeutic performance, safety, and consistency. The injection should only be administered by qualified healthcare professionals in hospitals, oncology centers, and specialized hematology treatment facilities.
Patients receiving Fludarabine therapy often require routine blood tests, immune system monitoring, kidney function assessments, and regular medical evaluations to ensure treatment effectiveness and minimize potential risks.
Due to its established role in treating blood cancers, FLULIEVA 50 MG remains an important component of modern leukemia and lymphoma management programs worldwide.
FLULIEVA 50 MG (Fludarabine Phosphate for Injection 50 mg) is primarily used for the treatment and management of blood cancers and lymphoid malignancies.
The medicine is widely used in patients diagnosed with chronic lymphocytic leukemia.
Doctors may prescribe Fludarabine for specific forms of B-cell leukemia requiring systemic treatment.
The medicine may be used in selected cases of low-grade or indolent non-Hodgkin lymphoma.
FLULIEVA may help manage cancers that have returned after previous treatment.
The medicine is frequently included in multi-drug treatment regimens.
Fludarabine supports comprehensive treatment strategies for various hematological disorders.
Fludarabine belongs to a class of medicines known as Purine Analog Antimetabolites.
FLULIEVA works by:
This mechanism helps slow the advancement of blood cancers and supports effective cancer management.
Like all chemotherapy medicines, FLULIEVA 50 MG may cause side effects in some patients. Side effects vary depending on treatment duration, dosage, and individual patient response.
Weakness and tiredness are commonly reported during treatment.
Mild fever may occur as a result of therapy.
Patients may experience mild to moderate nausea.
Some individuals may develop episodes of vomiting.
Reduced appetite may affect nutritional intake.
Digestive disturbances and loose stools may occur.
Fludarabine may weaken the immune system, increasing susceptibility to infections.
Respiratory symptoms such as cough may occasionally develop.
The medicine may reduce:
This may increase the risk of infections, anemia, and bleeding complications.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of FLULIEVA 50 MG (Fludarabine Phosphate for Injection 50 mg) should always be determined by a qualified hematologist or oncologist.
Treatment schedules vary depending on the diagnosed condition.
Dosage is commonly calculated according to body size.
Patients with kidney impairment may require dosage adjustments.
Treatment decisions often depend on laboratory test results.
Doctors may adjust therapy according to effectiveness and side effect management.
Before receiving treatment, patients should inform their doctor if they have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid possible drug interactions.
Pregnant or breastfeeding women should only receive this medicine if specifically recommended by a healthcare professional.
It is primarily used for the treatment of chronic lymphocytic leukemia and certain lymphoid malignancies.
Fludarabine Phosphate is a purine analog chemotherapy medicine that interferes with DNA synthesis in cancer cells.
Yes, it is a chemotherapy medicine used in hematology and oncology treatment programs.
Yes, it is often included in combination chemotherapy regimens.
Yes, the medicine may reduce immune function and increase susceptibility to infections.
Yes, treatment may lower white blood cells, red blood cells, and platelets, requiring regular monitoring.
Yes, doctors typically recommend blood tests, kidney function assessments, and routine medical evaluations throughout therapy.
Yes, this medicine should only be administered by qualified healthcare professionals experienced in hematology and oncology treatment.